These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32826630)

  • 1. Aerobic Fitness Is Related to Myocardial Fibrosis Post-Anthracycline Therapy.
    Kirkham AA; Paterson DI; Haykowsky MJ; Beaudry RI; Mackey JR; Pituskin E; Grenier JG; Thompson RB
    Med Sci Sports Exerc; 2021 Feb; 53(2):267-274. PubMed ID: 32826630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors.
    Jordan JH; Vasu S; Morgan TM; D'Agostino RB; Meléndez GC; Hamilton CA; Arai AE; Liu S; Liu CY; Lima JA; Bluemke DA; Burke GL; Hundley WG
    Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27502058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent Impairment in Cardiopulmonary Fitness after Breast Cancer Chemotherapy.
    Foulkes SJ; Howden EJ; Bigaran A; Janssens K; Antill Y; Loi S; Claus P; Haykowsky MJ; Daly RM; Fraser SF; LA Gerche A
    Med Sci Sports Exerc; 2019 Aug; 51(8):1573-1581. PubMed ID: 30829962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Cardiovascular Magnetic Resonance Tissue Characterization and Cardiotoxicity in Women With Breast Cancer.
    Thavendiranathan P; Shalmon T; Fan CS; Houbois C; Amir E; Thevakumaran Y; Somerset E; Malowany JM; Urzua-Fresno C; Yip P; McIntosh C; Sussman MS; Brezden-Masley C; Yan AT; Koch CA; Spiller N; Abdel-Qadir H; Power C; Hanneman K; Wintersperger BJ
    JAMA Cardiol; 2023 Jun; 8(6):524-534. PubMed ID: 37043251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.
    Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G
    BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrahigh-field cardiovascular magnetic resonance T1 and T2 mapping for the assessment of anthracycline-induced cardiotoxicity in rat models: validation against histopathologic changes.
    Park HS; Hong YJ; Han K; Kim PK; An E; Lee JY; Park CH; Lee HJ; Hur J; Kim YJ; Choi BW
    J Cardiovasc Magn Reson; 2021 Jun; 23(1):76. PubMed ID: 34134713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance.
    Jordan JH; D'Agostino RB; Hamilton CA; Vasu S; Hall ME; Kitzman DW; Thohan V; Lawrence JA; Ellis LR; Lash TL; Hundley WG
    Circ Cardiovasc Imaging; 2014 Nov; 7(6):872-9. PubMed ID: 25273568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients.
    Howden EJ; Bigaran A; Beaudry R; Fraser S; Selig S; Foulkes S; Antill Y; Nightingale S; Loi S; Haykowsky MJ; La Gerche A
    Eur J Prev Cardiol; 2019 Feb; 26(3):305-315. PubMed ID: 30376366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular magnetic resonance parametric techniques to characterize myocardial effects of anthracycline therapy in adults with normal left ventricular ejection fraction: a systematic review and meta-analysis.
    Musella F; Librera M; Sibilio G; Boccalatte M; Tagliamonte G; Cavaglià E; Ferrara I; Puglia M; Dell'Aversana S; Ducci CB; Dellegrottaglie S; Savarese G; Scatteia A
    Curr Probl Cardiol; 2024 Jul; 49(7):102609. PubMed ID: 38697332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular magnetic resonance characterisation of anthracycline cardiotoxicity in adults with normal left ventricular ejection fraction.
    Harries I; Berlot B; Ffrench-Constant N; Williams M; Liang K; De Garate E; Baritussio A; Biglino G; Plana JC; Bucciarelli-Ducci C
    Int J Cardiol; 2021 Nov; 343():180-186. PubMed ID: 34454967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early myocardial oedema can predict subsequent cardiomyopathy in high-dose anthracycline therapy.
    Muehlberg F; Kornfeld M; Zange L; Ghani S; Reichardt A; Reichardt P; Schulz-Menger J
    ESC Heart Fail; 2023 Feb; 10(1):616-627. PubMed ID: 36404640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
    Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG
    JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Native Myocardial T1 Mapping for Early Detection of Anthracycline-Induced Cardiotoxicity in Patients with Cancer: a Systematic Review and Meta-analysis.
    Mohamed AA; Elmancy LY; Abulola SM; Al-Qattan SA; Mohamed Ibrahim MI; Maayah ZH
    Cardiovasc Toxicol; 2024 Jun; 24(6):563-575. PubMed ID: 38700665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling.
    Tham EB; Haykowsky MJ; Chow K; Spavor M; Kaneko S; Khoo NS; Pagano JJ; Mackie AS; Thompson RB
    J Cardiovasc Magn Reson; 2013 Jun; 15(1):48. PubMed ID: 23758789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy.
    Koelwyn GJ; Lewis NC; Ellard SL; Jones LW; Gelinas JC; Rolf JD; Melzer B; Thomas SM; Douglas PS; Khouri MG; Eves ND
    Oncologist; 2016 Feb; 21(2):141-9. PubMed ID: 26764251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late characterisation of cardiac effects following anthracycline and trastuzumab treatment in breast cancer patients.
    Kimball A; Patil S; Koczwara B; Raman KS; Perry R; Grover S; Selvanayagam J
    Int J Cardiol; 2018 Jun; 261():159-161. PubMed ID: 29576422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac and skeletal muscle predictors of impaired cardiorespiratory fitness post-anthracycline chemotherapy for breast cancer.
    Kirkham AA; Haykowsky MJ; Beaudry RI; Grenier JG; Mackey JR; Pituskin E; Paterson DI; Thompson RB
    Sci Rep; 2021 Jul; 11(1):14005. PubMed ID: 34234163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy.
    Muehlberg F; Funk S; Zange L; von Knobelsdorff-Brenkenhoff F; Blaszczyk E; Schulz A; Ghani S; Reichardt A; Reichardt P; Schulz-Menger J
    ESC Heart Fail; 2018 Aug; 5(4):620-629. PubMed ID: 29673122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of routine pretreatment evaluation of left ventricular ejection fraction in breast cancer patients receiving anthracyclines.
    Peddi P; Master SR; Dwary AD; Ravipati HP; Patel AH; Pasam A; Katikaneni PK; Shi R; Burton GV; Chu QD
    Breast J; 2019 Jan; 25(1):62-68. PubMed ID: 30592128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease.
    Ferreira de Souza T; Quinaglia A C Silva T; Osorio Costa F; Shah R; Neilan TG; Velloso L; Nadruz W; Brenelli F; Sposito AC; Matos-Souza JR; Cendes F; Coelho OR; Jerosch-Herold M; Coelho-Filho OR
    JACC Cardiovasc Imaging; 2018 Aug; 11(8):1045-1055. PubMed ID: 30092965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.